Current Report · Items 5.07 · 8-K
Aptevo Therapeutics Inc.
APVONASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present.…
Filed Aug 21, 2026Accepted Aug 21, 2026, 4:05 PM EDTCIK 1671584Accession 0001193125-26-361079
Company context
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trial, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types.
Current securities
Historical securities (1)
Disclosure sections
Items 5.07Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on July 31, 2026 (the “Proxy Statement”). The final voting results with respect to each of the proposals acted upon at the 2026 Annual Meeting are set forth below.
Proposal 1: Election of Directors
The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes:
FOR WITHHELD BROKER NON-VOTES
───────────────────────────────────────────────────────────────────────────
Zsolt Harsanyi, Ph. D. 216,997 17,454 402,427
Barbara Lopez Kunz 211,050 23,401 402,427
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2026
The appointment of Baker Tilly US, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was approved based on the following votes:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
606,661 28,847 1,370 0
Proposal 3: Advisory Vote on Company's 2025 Executive Compensation
The non-binding advisory vote on the compensation paid to our named executive officers was approved based on the following votes:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
165,615 24,031 44,805 402,427
Proposal 4: Approval of the Company's Fourth Amended and Restated 2018 Stock Incentive Plan
The Aptevo Therapeutics Inc. Fourth Amended and Restated 2018 Stock Incentive Plan was approved based on the following votes:
FOR AGAINST ABSTAIN BROKER NON-VOTES
───────────────────────────────────────────────────────────
166,484 64,248 3,719 402,427